News | Proton Therapy | September 20, 2019

Varian Announces Multi-room Configuration for ProBeam 360 Proton Therapy System

ProBeam 360 offers 30 percent smaller footprint than Varian’s previous multi-room solution

Varian Announces Multi-room Configuration for ProBeam 360 Proton Therapy System

September 20, 2019 — Varian announced its ProBeam 360° proton therapy system is now available in a multi-room configuration. The ProBeam 360° system is what Varian calls the smallest multi-room system available for sale, with up to a 30 percent smaller footprint than the company's previous multi-room solution.

The ProBeam 360° system in a multi-room configuration allows cancer centers to tailor the system to meet their clinical, research and capacity needs. Treatment room options include 360-degree rotating gantries and fixed beam rooms. Research rooms are also available to satisfy a variety of non-clinical proton beam applications. In addition to the smaller footprint, the multi-room ProBeam 360° system occupies up to 50 percent less volume, reducing vault construction costs by approximately 25 percent.

The ProBeam 360° system features a powerful particle accelerator to treat cancer, a 360-degree gantry for clinical efficiency, and iterative cone-beam computed tomography (CBCT) imaging and high-definition pencil-beam scanning for high precision. The system can also provide clinicians a viable path to potential next-generation treatments such as FLASH therapy. (FLASH therapy is under preclinical research and is not available for clinical use, with no guarantee of future commercialization.)

For more information:

Related Content

IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...
An artificial intelligence (AI) program can spot signs of lung cancer on computed tomography (CT) scans a year before they can be diagnosed with existing methods, according to research presented at the European Respiratory Society International Congress.

Diagram showing details of the lung screening experiment. Image courtesy of the European Respiratory Society/Benoit Audelan

News | Artificial Intelligence | September 08, 2021
September 8, 2021 — An artificial intell...
Cedars-Sinai Cancer researchers have discovered that intestinal microorganisms help regulate anti-tumor immune responses to radiation treatments.

Getty Images

News | Radiation Therapy | September 01, 2021
September 1, 2021 — The study, published on Aug.